ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion
Julie A. Vendrell(Inserm), Pascale A. Cohen(Lyon 1 Université), Jean‐Luc Coll(Unknown), Evelyne Grisard(Lyon 1 Université), Ivan Bièche(Centre National de la Recherche Scientifique), Stéphanie Vinot(Lyon 1 Université), Ruth Rimokh(Lyon 1 Université), Véronique Josserand(Centre National de la Recherche Scientifique), Nhan Trung Nguyen(Lyon 1 Université), Isabelle Treilleux(Centre Léon Bérard), Pierre Roux(Centre National de la Recherche Scientifique), Laura Corbo(Centre National de la Recherche Scientifique), Sandra E. Ghayad(Inserm), Aurélie Thollet(Institut du Thorax)
Cited by 131
Related Papers
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
|Nature Genetics|2015|375
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302